louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05434702: "COACH" Study: Individualized COaching in Young Adult Cancer Survivors to Encourage Healthy Behaviors
Official title: The "COACH" Study: Individualized COaching in Young Adult Cancer Survivors to Encourage Healthy Behaviors
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Health Behavior
Keywords: Young Adult
Cancer survivor
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2022-06-28
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primarily participants in Moffitt Cancer Center's Adolescent and Young Adult Survivorship program

Brief summary: The purpose of this study is to better understand the current lifestyle behaviors that people with a young adult cancer diagnosis have after treatment. Investigators are also interested in understanding what affects the quality of life of young adult cancer survivors. Investigators will use this information to develop and test a diet and physical activity intervention to help young adult cancer survivors feel their best


Eligibility criteria: Inclusion Criteria:

* Diagnosed with cancer between the ages of 19 and 29
* Currently between the ages of 20 and 30 years old
* At least 1 year post-adjuvant therapy
* Able to read/speak English
* Able to complete an online survey
* Able to consume food orally

Exclusion Criteria:

* Women who are pregnant

Primary outcomes:
measure: Aim 1: Quality of Life in YA Cancer Survivors -EORTC-QOL
timeFrame: Week 1
measure: Aim 1: Quality of Life in YA Cancer Survivors -FACT-G
timeFrame: Week 1
measure: Aim 1: Physical Activity in YA cancer Survivors - Questionnaire
timeFrame: Up to 2 weeks
measure: Aim 1: Physical Activity in YA cancer Survivors - Fitbit data
timeFrame: Up to 2 weeks
measure: Aim 1: Healthy eating in YA cancer survivors
timeFrame: Up to 2 weeks
Secondary outcomes:
measure: Aim 2: Development of educational intervention for YA cancer survivors
timeFrame: Up to 24 months
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
Study officials:
affiliation: Moffitt Cancer Center
name: Heather S.L. Jim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01975402: Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population
Official title: Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Congestive Heart Failure
Keywords: Congestive Heart Failure
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Preventice
name: National Institute on Aging (NIA)
First posted: 2013-11-03
Enrollment: 42
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals \>50 years with Congestive Heart Failure

Brief summary: We will evaluate the end to end remote monitoring system in a less controlled environment and concurrently develop the infrastructure to support the back end of the system

Detailed description: The overall objective of our research is to test, adapt, refine and validate the BodyGuardian technology and related end-to-end remote monitoring system to be used outside usual medical care environments to reduce hospital readmissions and facilitate independent living for heart failure patients. An important component of our overall strategy for continued development and refinement of the remote monitoring system is the incorporation of iterative behavioral evaluations to facilitate assessment and refinement in order to optimize adherence, utilization, and usability for patients as well as efficiency and functionality for providers.

Eligibility criteria: Inclusion Criteria:

* Outpatients
* Stable New York Heart Association Class I-III HF (defined as no admissions for \> 1 year)
* Recruited from the Mayo Heart Failure Clinic, including 15 men and 15 women
* Age \> 50 years
* Reside in Olmsted County

Exclusion Criteria:

* Hospital admission for HF within past year
* Dementia
* Overall life expectancy \< 2 months
* Blindness
* Pregnancy or women able to become pregnant
* Skin allergy to adhesives
* Inadequate cell phone coverage (international patients or international travel during study period)
* Documented Ejection Fraction of \>40%

Primary outcomes:
measure: adherence and utilization of end-to-end system in 30 subjects with stable New York Heart Association class I-III Heart Failure for 2 weeks
timeFrame: 12 months
Secondary outcomes:
measure: effect of end-to-end system on life quality
timeFrame: 12 months
Other outcomes:
measure: Healthcare record integration
timeFrame: 12 months
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
city: Eau Claire
country: United States
facility: Mayo Clinic Health System-Eau Claire Hospital, Inc.
state: Wisconsin
city: La Crosse
country: United States
facility: Mayo Clinic Health System-Franciscan Medical Center
state: Wisconsin
Study officials:
affiliation: Mayo Clinic
name: Lyle J Olson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05048602: Drug-induced Brugada Syndrome Research Database
Official title: Drug-induced Brugada Syndrome Research Database
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Brugada Syndrome
Arrhythmia
ICD
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
First posted: 2021-09-17
Enrollment: 500
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with drug-induced Brudaga Syndrome

Brief summary: All patients with drug-induced Brugada syndrome who are evaluated and followed at each participating centers will be recorded in this register. Within this register a characterization of patients and therapy will be done. Prognostic factors of adefined clinical relevant endpoints will be evaluated.


Eligibility criteria: Inclusion Criteria:

* All consecutive patients with drug-induced Brugada Syndrome

Exclusion Criteria:

* Missing Informed Consent Form
* Missing Contact Informations for Follow up

Primary outcomes:
measure: Sudden Cardiac Death
timeFrame: 1 year
measure: Appropriate ICD Therapies
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Vincenzo Russo
state: Napoli
Study officials:
affiliation: University of Campania Luigi Vanvitelli
name: Vincenzo Russo, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00622102: Testing Strategies to Improving Warfarin Adherence
Official title: Testing Strategies to Improving Warfarin Adherence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Deep Venous Thrombosis
Dilated Cardiomyopathies
Keywords: warfarin
adherence
Mechanical heart valves
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: Aetna, Inc.
First posted: 2008-02-22
Enrollment: 101
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being asked to participate in order to see if a lottery which provides the opportunity to win money in combination with the use of the Med-eMonitor might be useful in helping patients to achieve better control of their anticoagulation therapy. Half of the participants will be enrolled in the lottery arm and the other half will be a control group who will receive the Med-eMonitor only.


Eligibility criteria: Inclusion Criteria:

* 21 years old age or older
* On warfarin managed at the AC clinic
* Target INR 2.0-3.0 or 2.5-3.5
* At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits)

Exclusion Criteria:

* Do not have access to telephone line
* Unwillingness to participate or to sign a consent form(refusal)
* Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor
* Participation in a current study that does not permit participation in another study
* End stage or terminal illness with anticipated life expectancy of 6 months or less
* INR over the upper limit for the individual's range at the time of enrollment (e.g.,\>3.0 or \>3.5, depending on the target range)
* Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin

Primary outcomes:
measure: anticoagulation control
timeFrame: six months
Secondary outcomes:
measure: adherence
timeFrame: six months
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania Anticoagulation Management Center
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Kevin G Volpp, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04624802: Maternal Exercise and Antenatal Anxiety
Official title: The Effect of Maternal Exercise on Anxiety During Normal Pregnancy：a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anxiety
Keywords: anxiety
pregnancy
exercise
Lead sponsor: Shenzhen Second People's Hospital
Sponsor class: OTHER
First posted: 2020-11-12
Enrollment: 220
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized controlled trial study. We evaluate effectiveness of maternal exercise on anxiety during normal pregnancy compared to those who receive antenatal care regularly. We plan to recruit 220 healthy pregnant women over the age of 18 in Shenzhen and to use a standard maternal exercise from Korea as intervention.


Eligibility criteria: Inclusion Criteria:

* Pregnant women who are over 18 years old and confirmed to be pregnant in Shenzhen Dapeng New District.

Exclusion Criteria:

* 1.pregnant women who have accepted maternal exercise training (at least twice a week in last month);2.pregnant women who have orthopedics, cardiovascular or mental diseases; 3.pregnant women who have or had any condition as follows:miscarriage more than two times,premature delivery,placenta previa,fetal dysplasia, low weight before pregnancy (BMI \<17.5),polycyesis,preeclampsia,premature rupture of membranes,Uterine growth retardation,cervical/ligation,repeated vaginal bleeding,anemia or diabetes; 4.the gestational age is less than 12 weeks or more than 16 weeks;5.received psychotherapy or psychotropic medication within 6 months before the study;6.can not participate in regular inspections.

Primary outcomes:
measure: Change from Baseline of State Anxiety at 32 Weeks of Gestation
timeFrame: The participants are examined between 12 and 16 weeks of gestation (baseline visit) and at gestation week 32 (after the intervention).
Secondary outcomes:
measure: Change from Baseline of Depressive Symptom at 32 Weeks of Gestation
timeFrame: The participants are examined between 12 and 16 weeks of gestation (baseline visit) and at gestation week 32 (after the intervention).
measure: Change from Baseline of Pain at 32 Weeks of Gestation
timeFrame: The participants are examined between 12 and 16 weeks of gestation (baseline visit) and at gestation week 32 (after the intervention).
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06695702: Cancer Symptom Management in Nursing Students
Official title: The Effect of Collaborative Learning Approach with Concept Maps on Nursing Students' Knowledge Learning on Symptom Management in Cancer Patients: a Randomized Controlled Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nursing Students
Keywords: oncology
nursing student
Collaborative Learning Approach
Lead sponsor: Bilecik Seyh Edebali Universitesi
Sponsor class: OTHER
First posted: 2024-11-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: nursing students

Brief summary: Ensuring that nursing students learn the symptoms seen in cancer.

Detailed description: Nursing education plays an important role in providing the knowledge, skills and critical thinking abilities needed to provide quality care. Innovative teaching strategies provide quality education. These methods, such as cooperative learning and concept maps, help them to criticize and apply their knowledge. It is important to integrate these strategies in oncology nursing education, which involves complex treatment processes and symptom management. Collaborative learning with concept maps can contribute to the development of a more holistic understanding of oncology care. This study was planned to examine the effect of collaborative learning approach with concept maps on nursing students' knowledge learning about symptom management of oncologic patients.

Eligibility criteria: Inclusion Criteria:

* The sample of the study will consist of students who were attending the course on the date the research data were collected,
* who had not received education for oncology patients before and
* who agreed to participate in the study.
* It will be aimed to include all students who meet the inclusion criteria.

Exclusion Criteria:

* Students who were absent from the course and
* did not participate in the pre-test, post-test and follow-up test will be excluded from the study.

Primary outcomes:
measure: questionnaire on knowledge of oncologic symptoms
timeFrame: 14/11/2024-31/12/2024
Secondary outcomes:
Other outcomes:
Locations:
city: Bilecik
country: Turkey
facility: Bilecik Şeyh Edebali University
Study officials:
References:
Clinical trial NCT03519802: Evaluation of Cognitive Function in a Suicidal Crisis
Official title: Evaluation of Cognitive Function in a Suicidal Crisis and Interest to Achieve a MoCA Test in Acute Situations
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Suicide
Keywords: Cognitive functions
MoCA test
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2018-05-09
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients hospitalized for less than a week and presenting with a suicidal crisis

Brief summary: The aftermath of suicide is devastating, being the cause of 800 000 deaths every year worldwide. In France, suicide still causes about 10 000 deaths per year and the number of suicide attempts (SA) is estimated between 170 000 and 200 000 per year (InVS).

It is often thought that a suicidal crisis is only related to depression, as it actually is a far more complex phenomenon. A suicidal crisis can occur on various grounds like psychiatric disorders but also contextual events or somatic diseases and it has been hypothesized that suicidal ideas or inclinations could have a common and independent cognitive origin


Eligibility criteria: Inclusion Criteria:

* Normal or corrected vision
* Having understood the information not and having signed the form of consent
* Being hospitalized for suicidal ideas (Score with inclusion at the level of Beck \> 3) or after a suicide attempt of less than one week.

Exclusion criteria:

* Pregnant woman and/or nursing
* Diagnosed irrational pathology
* Known proven intellectual deficiency
* Patient whose physical or mental status does not allow to pass the tests of the study
* Being under supervision or trusteeship or private of freedom or in emergency

Primary outcomes:
measure: Rate of patients having a score in MoCA test strictly under 26
timeFrame: at inclusion
Secondary outcomes:
measure: Variation in MoCA test scores between before (V1) and after hospitalization (V2)
timeFrame: an average at 3 months after inclusion
measure: Variation in scores to the subtests between between before (V1) and after hospitalization (V2)
timeFrame: an average at 3 months after inclusion
measure: Rate of patients having lower subtests scores than the standards
timeFrame: an average at 3 months after inclusion
Other outcomes:
Locations:
city: Lille
country: France
facility: CHRU,Hôpital Fontan
Study officials:
affiliation: University Hospital, Lille
name: Vincent JARDON, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06427902: Inflammatory Biomarkers in Saliva at Depression
Official title: Salivary Biomarkers of Gingival Inflammation Are Associated With Depression
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gingivitis
Depression
Inflammation
Inflammatory Response
Lead sponsor: Medipol University
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Maximum age (years): 53
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This study was carried out on 65 participants in total, including 42 individuals who applied to Aydın State Hospital Psychiatry Outpatient Clinic, diagnosed with depressive disorder, were classified in 2 different groups; depression with gingivitis (DG), depression with periodontally healthy (DPH) patients and 23 systemically and periodontally healthy (SPH) individuals who applied to Adnan Menderes University Faculty of Dentistry.

Brief summary: The goal of this observational study is to evaluate the inflammatory saliva biomarkers in depression and gingivitis.

The main question will be ; Will there be an increase at salivary biomarkers with depression patients and is it associated with gingivitis?

Detailed description: Background: The neuroimmune regulation disorder in depression patients causes the progression of inflammatory periodontal disease. The present study was to evaluate the periodontal health status and the levels of Triggering receptor expressed on myeloid cells 1 (TREM-1), peptidoglycan recognition protein 1 (PGLYRP1) and interleukin-1 beta (IL-1β) in individuals diagnosed with depression and to compare these findings with those of systemically healthy individuals.

Methods: Forty-two depression patients were classified in two groups: depression with gingivitis (DG) and depression with periodontally healthy (DPH) patients. Additionally, 23 systemically and periodontally healthy (SPH) individuals were enrolled to the study. Periodontal parameters were recorded. Saliva samples were collected and salivary levels of TREM-1, PGLYRP1, IL-1β were measured using Enzyme-linked Immunosorbent Assay (ELISA) kits.

depression regardless of periodontal status.

Eligibility criteria: Inclusion Criteria:

* Patients who were moderate in severity according to the test result, who had not started drug therapy yet and who had not received antidepressant medication in the last 12 months

Exclusion Criteria: Patients with

* psychotic disorders
* autism spectrum disorders
* other anxiety disorders
* bipolar disorder
* mental any organic mental disorder and
* smokers, substance users

Primary outcomes:
measure: SalivaryTREM-1
timeFrame: 06-09 2019
measure: Salivary PGLYRP1
timeFrame: 06-09 2019
measure: Salivary IL-1β
timeFrame: 06-09 2019
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Duygu Ilhan
state: Select State
Study officials:
References:
Clinical trial NCT01480102: Paravertebral Block for Percutaneous Nephrolithotomy
Official title: Paravertebral Block for Percutaneous Nephrolithotomy (PRONE)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post Operative Pain
Keywords: Percutaneous nephrolithotomy
Paravertebral block
bupivacaine
Lead sponsor: Loyola University
Sponsor class: OTHER
First posted: 2011-11-28
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare post-operative pain levels in patients who receive paravertebral block prior to Percutaneous Nephrolithotomy (PCNL) surgery versus those who do not receive the block. We hypothesize that patients who receive the block will have lower post-operative pain scores and require less narcotics.

Detailed description: The strategies used to manage nephrolithiasis including medical expulsive therapy, extracorporeal shock wave (ESWL), ureteroscopy, open surgery and percutaneous nephrolithotomy (PCNL). PCNL in an inpatient procedure performed in two steps. Step 1, is the placement of a drainage line (nephrostomy tube) from the back into the collecting system of the kidney. This step is typically performed by interventional radiologists under conscious sedation. Step 2 is performed by urologists and involves dilating the tract of the nephrostomy tube, placement of an access sheath and actual removal of the stone using endoscopic equipment. The minimally invasive approach of PCNL is well accepted to be as effective as open procedures for stone removal with less morbidity. Post-operative pain management remains challenging and can lead to extended hospital stays.

This randomized, double-blinded trial designed to assess the effects of paravertebral block on intra-operative and post-operative pain control.

Eligibility criteria: Inclusion Criteria:

* Consent to undergo percutaneous nephrolithotomy
* Between the ages of 18 and 75
* Able to consent, fill out study documents, and complete all study procedures and follow-up visits

Exclusion Criteria:

* Will have bilateral percutaneous nephrolithotomy
* Have an infection at the site of the proposed block
* Have anatomy that prevents ability to perform block
* Have a coagulopathy which may increase their chances of bleeding from the block
* Have a known allergy to local anesthetics
* Are unable to fill out the VAS scale due to physical or mental conditions
* Are unable to use a patient controlled analgesia (PCA) device due to physical or mental conditions
* Are pregnant

Primary outcomes:
measure: Pain Score
timeFrame: 24 hours
Secondary outcomes:
measure: Opiod Use
timeFrame: 24 hours
Other outcomes:
Locations:
city: Maywood
country: United States
facility: Loyola University Medical Center
state: Illinois
Study officials:
affiliation: Loyola Medical Center
name: Thomas Turk
role: PRINCIPAL_INVESTIGATOR
References: